Phillips Medisize announced that its parent company Molex has completed its acquisition of inhalation CDMO Vectura, which was initially announced in September 2024. According to the announcement, the acquisition covers all of Vectura’s assets in addition to its OINDP analysis and development services business, which employs 350 people. Vectura’s intellectual property includes devices such as the FOX nebulizer, the Gyrohaler and Lever Operated Multi-dose Inhaler (LOMI) DPIs, and MDIs.
Prior to being acquired by tobacco company Philip Morris International in 2021, Vectura had previously acquired several other companies in the inhalation space: Activaero in 2014 and Skyepharma in 2016. Phillips Medisize, which offers medical devices and CDMO services, was acquired by Molex in 2016.
Vectura’s Chief Scientific Officer Geraldine Venthoye has been named Chief Scientific Officer and Vice President for the Phillips Medisize Medical business. Venthoye commented, “The Vectura team is delighted with the completion of the acquisition. We are excited about the opportunities and scale of Phillips Medisize, which will allow us to deliver our formulation and combination product expertise to more pharmaceutical customers as part of end-to-end pharmaceutical development.”
Phillips Medisize President Paul Chaffin said, “Phillips Medisize will continue to expand the services we offer pharmaceutical companies thanks to the acquisition of Vectura, particularly in inhalation, to help meet growing patient needs. Together Phillips Medisize and Vectura are uniquely positioned to collaborate with leading pharmaceutical customers to develop innovative products that address the growing global demand for new therapies to treat chronic respiratory diseases like asthma and COPD, as well as non-respiratory conditions.”
Molex CEO Joe Nelligan added, “The acquisition of Vectura reflects our commitment to advancing industry-leading medical capabilities for our customers. Together Phillips Medisize and Vectura will unlock significant growth potential to support the growing need for inhalation therapies.”
Read the Phillips Medisize press release
